Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and pharmacodynamics of rhIGF-I in ALS deficiency
2010-019296-30Phase 4Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecasermin in Acid-labile subunit deficiency (ALSD) and growth hormone deficiency (GHD), sponsored by University Hospitals Birmingham. Primary endpoints: Pharmacokinetic variables of IGF-1 and Pharmacodynamic response and insulin measures. Started Apr 2010; status: completed.
02
Drugs
mecasermin
03
Conditions
Acid-labile subunit deficiency (ALSD)growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2010-019296-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019296-30.